Find out how integrative care for cardiorenal syndrome can provide comprehensive solutions for better patient management.

Abstract

Welcome to our educational series. I am Dr. Alex Jimenez, and I am honored to guide you through the intricate relationship between the heart and the kidneys, a condition known as Cardiorenal Syndrome (CRS). This post will delve into the critical diagnostic workup for patients presenting with symptoms like shortness of breath and fluid overload, explore the deep physiological crosstalk between these two vital organs, and detail the evidence-based management strategies we use in our practice. Drawing upon the latest findings from leading researchers, we will explore the pathophysiology of how heart failure leads to chronic kidney disease and vice versa. We will discuss the hormonal tug-of-war between the heart’s natriuretic peptides and the kidney’s renin-angiotensin-aldosterone system (RAAS), the role of inflammation and oxidative stress, and the critical concept of venous and abdominal congestion. A key aspect of our approach is the integration of multidisciplinary care. Here at Injury Medical Clinic PA, I work closely with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a board-certified internist with over 40 years of experience, and her medical oversight is invaluable. Together, we blend chiropractic care, functional medicine, rehabilitation, and conventional medicine to provide a comprehensive, holistic treatment plan for our patients, focusing on structural integrity, neurohormonal balance, and overall well-being.

Our Integrative Approach at Injury Medical Clinic

At our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have cultivated a truly multidisciplinary environment. I am Dr. Alex Jimenez, and my background as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), and Board-Certified Family Nurse Practitioner (FNP-BC), combined with my certifications as a Certified Functional Medicine Practitioner (CFMP), allows me to view health through multiple lenses—structural, functional, and systemic.

This is powerfully complemented by the expertise of our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749; Texas MD License #J2933). Dr. Cardenas is Board Certified in Internal Medicine and brings over four decades of clinical experience to our team. This collaborative setup, where an MD provides medical direction alongside a chiropractor and other specialists, is the cornerstone of modern integrative care. It allows us to seamlessly integrate multiple disciplines to create a personalized, comprehensive treatment plan for each patient. For instance, while I may focus on chiropractic adjustments to improve nervous system function and address musculoskeletal imbalances, Dr. Cardenas provides essential medical oversight, managing pharmacological interventions and diagnosing complex internal conditions. Together, our team focuses on functional medicine, rehabilitation, and personal injury care, addressing the patient as a whole person rather than just a collection of symptoms. This is particularly crucial when dealing with intricate systemic issues like cardiorenal syndrome.

The Heart-Kidney Connection: A Complex Tug-of-War

I want to take you on a journey into one of the most fascinating and challenging areas of medicine: the relationship between the heart and the kidneys. I often refer to this dynamic as a physiological “crosstalk” or a “tug-of-war.” When one of these organs begins to struggle, the other is inevitably affected. This is especially true in patients with acute decompensated heart failure, where acute kidney injury is incredibly common.

To truly understand how to manage this condition, we first need to appreciate the deep-seated connection between these two systems. It might be surprising to think of the heart as an endocrine organ, but it absolutely is. The heart produces several natriuretic peptides, including:

• Atrial Natriuretic Peptide (ANP)
• B-type Natriuretic Peptide (BNP)
• C-type Natriuretic Peptide (CNP)

These hormones function within a negative feedback loop, much like other hormones in the endocrine system. Their primary role is to promote vasodilation (widening of blood vessels), natriuresis (excretion of sodium in the urine), and subsequently, the loss of excess fluid. They are the body’s natural “relax and release” system.

On the other side of this tug-of-war are the kidneys, which regulate the powerful Renin-Angiotensin-Aldosterone System (RAAS). This system releases hormones that have the opposite effect:

• Renin and Angiotensin: These cause potent vasoconstriction, increasing blood pressure.
• Aldosterone: This hormone signals the body to retain sodium and water, increasing blood volume.

So, you have the heart’s hormones trying to lower blood pressure and shed fluid, while the kidney’s hormones are working to raise blood pressure and retain fluid. In a healthy state, these two systems exist in a delicate balance. However, in the context of disease, this balance is lost. When we see elevated BNP levels in a patient, it’s not just a simple sign of a stretched, fluid-overloaded heart. It’s an indicator of a profound endocrine response. Think of it like a high TSH level in hypothyroidism; the pituitary gland is screaming at the thyroid to work harder. Similarly, a high BNP shows the heart is desperately trying to counteract the overwhelming effects of a dominant RAAS. A key thing to remember is that in this hormonal battle, the kidney is the stronger endocrine organ. Over time, the kidney will almost always win this fight, leaving the heart at a disadvantage.

Unraveling the Pathophysiology of Cardiorenal Syndrome

The pathway from heart failure to kidney dysfunction is a cascade of events that feeds upon itself. Understanding this is crucial because it dictates every therapeutic decision we make.

Initial Insult and Compensatory Mechanisms

It all begins with heart failure. For a multitude of reasons, the heart’s ability to pump effectively is compromised. This immediately leads to two primary problems:

1. Decreased Cardiac Output: The heart isn’t pumping enough blood to meet the body’s demands.
2. Increased Preload: Blood backs up into the system, increasing pressure within the heart’s chambers (central filling pressures).

The body, evolutionarily primed to interpret a drop in blood pressure as a sign of bleeding or trauma, initiates several compensatory mechanisms to survive. These are meant to be short-term fixes, but in a chronic condition like heart failure, they become maladaptive.

• RAAS Activation: The kidneys sense the drop in blood flow and pressure. They think the body is “bleeding out” and immediately activate the RAAS. This leads to vasoconstriction, raising blood pressure, and the release of aldosterone, which promotes sodium and water retention, aiming to “refill the tank.”
• Sympathetic Nervous System (SNS) Activation: The “fight or flight” response kicks in. The SNS stimulates an increase in heart rate to compensate for the falling stroke volume (since Cardiac Output = Heart Rate × Stroke Volume). It also triggers a systemic inflammatory response, releasing inflammatory cytokines.

For a short period, this works. The body stabilizes. The problem is, heart failure isn’t a short-term issue. It’s a chronic state of low output and high filling pressures.

The Shift to Maladaptive Responses

This chronic activation of the RAAS and SNS begins to cause direct damage. The constant exposure to inflammatory cytokines and vasoconstrictive hormones leads to glomerular and interstitial damage within the kidneys. The delicate filtering units, the nephrons, become inflamed, scarred (sclerosis and fibrosis), and less effective. This is the very mechanism by which heart failure directly causes chronic kidney disease.

This damage creates a vicious cycle.

• Worsening kidney function further activates the RAAS.
• Chronic fluid retention from aldosterone overload leads to more peripheral edema (in the lungs, abdomen, and limbs).
• Systemic vasoconstriction puts even more strain on an already failing heart, worsening cardiac performance.

You can see how everything begins to spiral. We’re no longer just dealing with a heart problem; we’re dealing with a runaway train of systemic dysfunction where each component makes the others worse.

Deeper Dive: Neurohormonal and Hemodynamic Factors

Beyond this primary pathway, other factors compound the problem. These include specific neurohormonal changes and hemodynamic factors that we must consider in our treatment approach.

The Role of Inflammation and Oxidative Stress

The overactivation of the sympathetic nervous system does more than increase heart rate. It floods the body with reactive oxygen species (ROS), which are highly damaging byproducts of inflammation. This state of oxidative stress accelerates damage in both the heart and the kidneys.

• In the Heart: ROS leads to more scarring and sclerosis of the myocardium (heart muscle), causing adverse cardiac remodeling and further reducing the heart’s pumping ability.
• In the Kidney: We see profound renal tubular injury. This injury not only directly impairs kidney function but also independently stimulates further RAAS activation within the kidney itself. Now, the RAAS is being activated by both poor cardiac output and direct kidney injury.

This inflammatory damage leads to apoptosis, or programmed cell death. As kidney and heart cells die, they are replaced by non-functional scar tissue, a process known as fibrosis. We also observe a phenomenon called vacuolization in the distal tubules of the nephrons. These vacuoles take up space, reducing the surface area available for water removal and rendering the tubules ineffective.

The Hidden Impact of Abdominal Congestion

One of the most underappreciated aspects of heart failure is abdominal congestion. When we picture a classic heart failure patient, we often think of swollen ankles and legs (peripheral edema). However, the lower extremities are often the last place the body stores excess fluid. Long before the ankles swell, fluid has been accumulating elsewhere.

A primary reservoir for this fluid is the splanchnic venous system, which is the network of veins surrounding the liver, spleen, and intestines. As fluid backs up due to high pressures on the right side of the heart, this area becomes engorged. When I assess patients with advanced heart failure, I pay close attention to this compartment. We often see splenomegaly, hepatic congestion, intestinal wall edema, and abdominal wall edema on CT. These changes are not ascites; rather, they reflect interstitial and vascular congestion, with engorgement of the abdominal vasculature, including the portal and splenic veins, and a plump inferior vena cava (IVC) that fails to collapse on inspiration—an ultrasound sign consistent with elevated right-sided pressures. This leads to several critical problems:

• Increased Intra-abdominal Pressure: This pressure physically compresses the kidneys and the renal veins, directly impairing blood flow and filtration. This is a purely mechanical reason for worsening kidney function.
• Gut Edema and Bacterial Translocation: The intestinal walls become swollen and leaky. This allows gut bacteria and their inflammatory byproducts (endotoxins) to “translocate” into the bloodstream, fueling the systemic inflammatory fire that is already raging. This further damages the heart and kidneys.
• Hepatic Congestion: The liver becomes congested with fluid, impairing its ability to metabolize medications (including diuretics) and synthesize essential proteins. This is why we often see what’s called cardiac hepatopathy or congestive hepatopathy in these patients.

From Pre-Renal to Cardiorenal to Veno-Renal: A Clinical Evolution

Historically, management of heart failure prioritized left ventricular contractility. Over the last four decades, better hemodynamic profiling revealed that right ventricular (RV) function and venous pressures critically shape outcomes. We’ve moved beyond simplistic “pre-renal” labeling to appreciate cardiorenal syndromes where heart failure drives renal injury. Now, modern evidence and practice foreground a veno-renal state, in which venous hypertension is the primary disruptor of renal filtration.

The kidneys depend on a pressure gradient between arteriolar inflow at the glomerulus and venous outflow through the renal vein. When venous congestion raises pressure in the IVC and renal veins, the gradient narrows. Even with adequate arterial pressure, glomerular filtration rate (GFR) drops because the transcapillary pressure difference diminishes. This understanding has refined how I manage acute decompensated heart failure (ADHF) with renal involvement. We are not just pushing forward flow; we are actively relieving venous congestion to restore the kidney’s physiologic gradient.

The Initial Diagnostic Workup: Uncovering the Root Cause

When a patient presents to me with dyspnea (shortness of breath), my first step is to cast a wide diagnostic net. A thorough initial workup is crucial to build a clear clinical picture.

• Complete Blood Count (CBC): This fundamental test helps me rule out anemia as a cause of dyspnea and evaluate for infection (e.g., a white blood cell count of 20,000 suggests sepsis). Severe anemia can masquerade as heart failure; I have seen hemoglobin of 5 g/dL in patients presumed to have decompensated HF—anemia was the primary driver.
• Comprehensive Metabolic Panel (CMP): I prefer a CMP over a basic metabolic panel because it includes liver function tests. The liver and kidneys are what I call “ride or die friends”—they work together and often fail together. Hepatic congestion can manifest as elevated AST, ALT, and bilirubin levels.
• B-type Natriuretic Peptide (BNP or pro-BNP): This is a key biomarker for heart failure, helping quantify the degree of cardiac wall stress.
• Lactate: Lactate levels are often under-checked. An elevated lactate level is fundamentally an indicator of poor perfusion. It helps me risk-stratify my patients and decide if they require more aggressive interventions like inotrope support.
• Troponin: I order a troponin test to assess for myocardial injury. A significant elevation could indicate an acute myocardial infarction (MI) as the precipitating event.
• Urinalysis and Urine Microalbumin: I’m looking for protein. Significant proteinuria can suggest a chronic process. Microalbuminuria is an early sign of kidney damage, especially in patients with diabetes or hypertension. We must also keep conditions like glomerulonephritis on our differential diagnosis.

How We Establish Baseline Renal Function Before Acting

When a patient arrives with a reported creatinine of 1.9 mg/dL, I immediately ask: Is this truly acute kidney injury (AKI) or a chronic baseline? I review longitudinal labs. If prior values are 1.8, 1.7, and 1.9, the current value of 1.9 may reflect stable CKD rather than AKI. I rely on estimated GFR (eGFR) over creatinine alone for clinical decisions, as creatinine can be misleading due to muscle mass and diet. This distinction is vital for setting realistic treatment goals.

Advanced Imaging and Assessments

• Echocardiogram: My general rule is to order an echo if the patient hasn’t had one in the last six months. It provides a wealth of information about the heart’s structure and function.
• Renal Ultrasound: This is crucial to rule out a post-obstructive process such as hydronephrosis (swelling of a kidney due to a buildup of urine). I once cared for a patient with heart failure and an AKI whose underlying problem was a neurogenic bladder from diabetes. Decompressing his bladder resolved his AKI.
• 12-Lead EKG: An EKG is essential for detecting signs of ischemia or an acute MI and for identifying other triggers, such as new-onset atrial fibrillation.

The Importance of the Physical Assessment

A detailed physical assessment provides invaluable information. I always hone in on a patient’s New York Heart Association (NYHA) Functional Classification to understand the real-world impact of their heart failure.

• Class I: No limitation of physical activity.
• Class II: Slight limitation. Comfortable at rest, but ordinary activity causes symptoms.
• Class III: Marked limitation. Comfortable at rest, but less-than-ordinary activity causes symptoms.
• Class IV: Unable to carry on any physical activity without discomfort. Symptoms are present even at rest.

I also ask specific, open-ended questions to uncover subtle signs of congestion and malperfusion:

• Orthopnea: Shortness of breath when lying flat. I’ll ask, “How many pillows do you sleep on?” Many patients abandon their beds for a recliner.
• Paroxysmal Nocturnal Dyspnea (PND): Waking up suddenly at night feeling breathless. Patients often describe this as a nighttime panic attack.
• Bendopnea: A specific sign where a patient gets short of breath simply from bending over to tie their shoes.
• Dyspnea on Exertion (DOE): I ask about specific functional activities, such as “Can you walk across the parking lot without stopping?”
• Other Signs: Other classic signs of congestion include weight gain, early satiety, and abdominal bloating. Signs of malperfusion include fatigue, intermittent confusion, and decreased urine output.

The Hemodynamic Profiles of Acute Heart Failure

To guide immediate treatment, we classify patients into four hemodynamic profiles:

1. Warm and Wet: Good perfusion (“warm”) but congested (“wet”). These patients have signs of fluid overload but no signs of malperfusion.
2. Cold and Wet: Poor perfusion (“cold”) and congested (“wet”). These patients have signs of both malperfusion and fluid overload.
3. Warm and Dry: Good perfusion (“warm”) and not congested (“dry”). This is the ideal state.
4. Cold and Dry: Poor perfusion (“cold”) but not congested (“dry”). These patients have signs of malperfusion without fluid overload.

This simple classification system, developed by pioneers in cardiology, is incredibly powerful for tailoring our therapeutic approach at the bedside.

Phenotypes of Cardiorenal Syndrome (CRS)

Understanding the different types of CRS helps us appreciate the underlying pathophysiology and frame our management approach.

• Type 1 (Acute Cardiorenal Syndrome): Acute heart failure leads to acute kidney injury.
• Type 2 (Chronic Cardiorenal Syndrome): Chronic heart failure causes progressive chronic kidney disease.
• Type 3 (Acute Renocardiac Syndrome): Acute kidney injury leads to acute cardiac dysfunction.
• Type 4 (Chronic Renocardiac Syndrome): Chronic kidney disease leads to cardiac dysfunction.
• Type 5 (Secondary Cardiorenal Syndrome): A systemic condition, such as sepsis, causes simultaneous dysfunction of both the heart and kidneys.

Integrative Treatment Strategies for Cardiorenal Syndrome

Our goal is to widen the renal gradient and decongest the patient. Effective diuresis lowers filling pressures, reduces LV wall stress, and restores renal filtration.

Diuretics as Cornerstone Therapy: Threshold, Ceiling, and Site of Action

To use diuretics well, you need three mental models: site of action, threshold, and ceiling.

• Site of action across the nephron: We can target different parts of the kidney’s filtering units. Loop diuretics (e.g., furosemide) work on the ascending limb of the loop of Henle, while thiazides work on the distal convoluted tubule and SGLT2 inhibitors work on the proximal convoluted tubule.
• Threshold and ceiling: Threshold is the minimum dose required for effect, which is higher in patients with renal impairment. Ceiling is the dose beyond which you get more side effects than benefit. Once you hit the ceiling of a loop diuretic, adding agents at other nephron sites (sequential nephron blockade) often works better than escalating the same drug.

In daily practice, the selection of loop diuretics matters. Oral furosemide bioavailability is highly variable (?10–100%), leading to unpredictable responses. Torsemide and bumetanide exhibit high and consistent bioavailability (?80–100%), improving outpatient reliability. I often prefer these for a more predictable effect.

Guideline-Directed Medical Therapy During Decongestion

As we diurese patients, we prioritize guideline-directed medical therapy (GDMT) to control the underlying heart failure. We use GFR thresholds to guide initiation:

• ARNI/ACEI/ARB and MRA: typically initiated if eGFR>30 mL/min/1.73 m².
• SGLT2 inhibitors can be started at eGFR> 20 mL/min/1.73 m²; they improve cardiorenal outcomes and reduce HF hospitalizations.
• Beta-blockers: initiated when the patient is more euvolemic and stable.

Advanced Therapeutic Interventions

If a patient remains oliguric despite optimal diuretics, we consider temporary support:

• Inotrope Support: Agents like dobutamine can improve cardiac contractility and vasodilation, reducing venous congestion and improving the renal perfusion gradient.
• Ultrafiltration and Dialysis: For extreme fluid overload, we consider direct fluid removal with ultrafiltration, CRRT, or hemodialysis in collaboration with nephrology.
• Mechanical Circulatory Support: In severe cases, devices like Impella can provide direct LV or RV unloading to reduce venous congestion and improve organ perfusion.

Beating the Odds: “Conquering Congestive Heart Failure”- Video

How Integrative Chiropractic Care Fits Physiologically

So, where does integrative chiropractic care fit into this complex picture? While a chiropractor cannot directly reverse heart failure or kidney disease, my role within our multidisciplinary team is to address the crucial structural and neurological components that influence overall systemic health.

1. Optimizing Nervous System Function: The autonomic nervous system (ANS) is the master regulator of organ function. Chronic stress from conditions like cardiorenal syndrome leads to sympathetic dominance. Chiropractic adjustments, particularly to the upper cervical and thoracic spine, can help modulate the ANS. By reducing nerve interference and promoting a shift toward parasympathetic activity, we can help mitigate the relentless SNS activation that drives inflammation, vasoconstriction, and tachycardia.
2. Addressing Biomechanical Stress: Postural imbalances place mechanical stress on the body. As a chiropractor, I identify and correct spinal misalignments (subluxations). By improving posture, we can reduce physical stressors, freeing up energy for healing. Correcting thoracic spine dysfunction, for example, can improve rib cage mechanics and diaphragmatic breathing, thereby positively influencing venous return to the heart.
3. Enhancing Fluid Dynamics and Venous Return: The lymphatic system relies on musculoskeletal movement to function. Manual therapies and rehabilitation exercises improve lymphatic drainage, helping to reduce congestion. Improving diaphragmatic excursion enhances intrathoracic pressure changes that facilitate venous return to the heart and promote IVC flow. Engaging the calf muscle pump through prescribed activity also materially improves lower-extremity venous return.
4. Functional Medicine Integration: My training in functional medicine allows me to work alongside Dr. Cardenas to address the root causes of inflammation and oxidative stress. This involves recommending specific nutritional strategies, targeted supplementation (e.g., CoQ10, omega-3 fatty acids), and lifestyle modifications that support both cardiac and renal health from a biochemical perspective.

By combining my chiropractic and functional medicine expertise with Dr. Cardenas’s internal medicine oversight, we provide a holistic approach. We are not just managing symptoms; we are addressing the underlying neuro-hormonal, inflammatory, and structural dysfunctions that perpetuate the cardiorenal cycle.

Closing Thoughts

Cardiorenal care in the context of venous congestion demands a broader lens that accounts for both forward output and backward pressures. As we deploy modern evidence and collaborative practice in El Paso, we see patients improve not only on monitors and labs but in their lived function—breathing easier, moving more, and stabilizing over time. That is the promise of integrative care: physiology guided by evidence, applied by a coordinated team.

References

• Anker, S. D., et al. (2009). Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine, 361(25), 2436–2448.
• Bart, B. A., Boyle, A., Bank, A. J., et al. (2012). Ultrafiltration in decompensated heart failure. Journal of the American College of Cardiology, 60(20), 1905–1912.
• Brater, D. C. (1998). Diuretic therapy. New England Journal of Medicine, 339(6), 387–395.
• Costanzo, M. R., et al. (2007). Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. Journal of the American College of Cardiology, 49(6), 675–683.
• Felker, G. M., et al. (2003). Hemodynamic trials in heart failure: a review of the literature. Journal of the American College of Cardiology, 41(9), 1514–1524.
• Felker, G. M., Lee, K. L., Bull, D. A., et al. (2011). Diuretic strategies in patients with acute decompensated heart failure (DOSE). New England Journal of Medicine, 364(9), 797–805.
• Heerspink, H. J. L., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436–1446.
• Hoguet, B. (2024). Cardiorenal Syndrome: A Deep Dive into Pathophysiology and Management. American Association of Nurse Practitioners (AANP) National Conference.
• House, A. A., & Wanner, C. (2020). Cardiorenal syndrome: An internist’s perspective. Clinical Journal of the American Society of Nephrology, 15(1), 102–110.
• Jimenez, A. (n.d.). Clinical Observations in Integrative and Functional Medicine. Chiropractic Scientist.
• Jimenez, A. (n.d.). Professional Profile and Experience. LinkedIn.
• McCullough, P. A., Kellum, J. A., Haase, M., Mueller, C., & Rosner, M. H. (2013). Pathophysiology of the cardiorenal syndromes: Executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contributions to Nephrology, 182, 82–98.
• McMurray, J. J. V., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
• Mozaffarian, D., et al. (2005). Fish intake, mercury, and the risks of cardiovascular diseases. New England Journal of Medicine, 350(3), 221–233.
• Mullens, W., et al. (2009). Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. Journal of the American College of Cardiology, 53(7), 589–596.
• Nohria, A., Lewis, E., & Stevenson, L. W. (2003). Medical management of advanced heart failure. JAMA, 290(6), 780–789.
• Pitt, B., Zannad, F., Remme, W. J., et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). New England Journal of Medicine, 341(10), 709–717.
• Rangisnan, G. (2018). The cardiorenal syndrome: A clinical review. Journal of the American College of Cardiology, 72(25), 3326- 3339.
• Ronco, C., McCullough, P. A., Anker, S. D., et al. (2010). Cardiorenal syndromes: Report from the consensus conference of the Acute Dialysis Quality Initiative. European Heart Journal, 31(6), 703–711.
• Stevenson, L. W. (1999). The management of acute decompensated heart failure. Heart, 81(3), 337–342.
• Yancy, C. W., Jessup, M., Bozkurt, B., et al. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation, 136(6), e137–e161.

SEO Tags: Cardiorenal Syndrome, Heart Failure, Chronic Kidney Disease, Integrative Chiropractic Care, Functional Medicine, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, El Paso, TX, Pathophysiology, RAAS, Sympathetic Nervous System, Abdominal Congestion, Inflammation, Oxidative Stress, Multidisciplinary Care, Dyspnea, Injury Medical Clinic, Acute Kidney Injury, Echocardiogram, NYHA Class, Bendopnea, Orthopnea, PND, Hemodynamic Profiles, Evidence-Based Medicine, Holistic Healthcare, venous congestion, veno-renal physiology, right ventricle function, inferior vena cava ultrasound, SGLT2 inhibitors, GFR thresholds, diuretic resistance, thoracic mobility, diaphragmatic breathing, personal injury rehabilitation, edema management, portal hypertension, loop diuretics dosing, torsemide vs furosemide, milrinone renal perfusion